Сахарный диабет 2-го типа и хроническая сердечная недостаточность: новые стратегии лечения

1. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614-9. DOI:10.2337/diacare.24.9.1614
2. Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32(5):915-20. DOI:10.2337/dc08-1709
3. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385(9982):2107-17. DOI:10.1016/S0140-6736(14)61402-1
4. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154-62. DOI:10.1007/s00125-012-2579-0
5. Kristensen SL, Preiss D, Jhund PS, еt al. PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1):e002560. DOI:10.1161/CIRCHEARTFAILURE.115.002560
6. Erqou S, Lee CT, Suffoletto M, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail. 2013;15(2):185-93. DOI:10.1093/eurjhf/hfs156
7. Parry HM, Deshmukh H, Levin D, et al. Both high and low HbA1c predict incident heart failure in type. 2 diabetes mellitus. Circ Heart Fail. 2015;8(2):236-42. DOI:10.1161/CIRCHEARTFAILURE.113.000920
8. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. DOI:10.1002/ejhf.592
9. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591-9. DOI:10.1016/j.amjmed.2006.05.024
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. DOI:10.1056/NEJM198706043162301
11. Standl E, Schnell O, McGuire DK. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circ Res. 2016;118(11):1830-43. DOI:10.1161/CIRCRESAHA.116.306924
12. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-26. DOI:10.1056/NEJMoa1307684
13. White WB, Cannon CP, Heller SR, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327-35. DOI:10.1056/NEJMoa1305889
14. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. DOI:10.1056/NEJMoa1501352
15. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI:10.1056/NEJMoa1504720
16. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526-34. DOI:10.1093/eurheartj/ehv728
17. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303
18. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190
19. American Diabetes Association. 2 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S13-S28.
DОI:10.2337/dci19-0066
20. Consentino F, Grant P, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486
21. Seferović PM, Fragasso G, Petrie M, et al. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(9):1495-503. DOI:10.1002/ejhf.1954
22. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный). Клинические рекомендации. М.: ФГБУ «НМИЦ эндокринологии», 2019 [Algorithms for specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, AYu Mayorov. 9th issue (revised). Clinical guidelines. Moscow: National Medical Research Center for Endocrinology, 2019 (in Russian)]. DOI:10.14341/DM221S1

________________________________________________

1. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614-9. DOI:10.2337/diacare.24.9.1614
2. Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32(5):915-20. DOI:10.2337/dc08-1709
3. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385(9982):2107-17. DOI:10.1016/S0140-6736(14)61402-1
4. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154-62. DOI:10.1007/s00125-012-2579-0
5. Kristensen SL, Preiss D, Jhund PS, еt al. PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1):e002560. DOI:10.1161/CIRCHEARTFAILURE.115.002560
6. Erqou S, Lee CT, Suffoletto M, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail. 2013;15(2):185-93. DOI:10.1093/eurjhf/hfs156
7. Parry HM, Deshmukh H, Levin D, et al. Both high and low HbA1c predict incident heart failure in type. 2 diabetes mellitus. Circ Heart Fail. 2015;8(2):236-42. DOI:10.1161/CIRCHEARTFAILURE.113.000920
8. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. DOI:10.1002/ejhf.592
9. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591-9. DOI:10.1016/j.amjmed.2006.05.024
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. DOI:10.1056/NEJM198706043162301
11. Standl E, Schnell O, McGuire DK. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circ Res. 2016;118(11):1830-43. DOI:10.1161/CIRCRESAHA.116.306924
12. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-26. DOI:10.1056/NEJMoa1307684
13. White WB, Cannon CP, Heller SR, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327-35. DOI:10.1056/NEJMoa1305889
14. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. DOI:10.1056/NEJMoa1501352
15. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI:10.1056/NEJMoa1504720
16. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526-34. DOI:10.1093/eurheartj/ehv728
17. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303
18. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190
19. American Diabetes Association. 2 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S13-S28.
DОI:10.2337/dci19-0066
20. Consentino F, Grant P, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486
21. Seferović PM, Fragasso G, Petrie M, et al. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(9):1495-503. DOI:10.1002/ejhf.1954
22. Algorithms for specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, AYu Mayorov. 9th issue (revised). Clinical guidelines. Moscow: National Medical Research Center for Endocrinology, 2019 (in Russian). DOI:10.14341/DM221S1

И.З. Бондаренко*1, М.Г. Бубнова2

1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
2 ФГБОУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия
*iz_bondarenko@mail.ru

________________________________________________

Irina Z. Bondarenko*1, Marina G. Bubnova2

1 Endocrinology Research Centre, Moscow, Russia;
2 National Research Center for Therapy and Preventive Medicine, Moscow, Russia
*iz_bondarenko@mail.ru